Ocular Therapeutix, Inc. (OCUL) investor relations documents from the company's IR site: 1 presentation; latest deck 2026-08-03. Read in-app with summaries. First-party data.
link opens in new tab: Post hoc analysis of AXPAXLI's treatment burden reduction, showing 56-72% improvement vs. Aflibercept.
| Published | Type | Document |
|---|---|---|
| 2026-08-03 | Presentation | link opens in new tab |
OCUL overview · OCUL earnings · OCUL financials · OCUL KPIs · OCUL documents · OCUL ownership · OCUL peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.